来自MSN5 个月
Sleep Apnea Device Marker Inspire's Stock Rises on Improved Outlook
The sleep apnea device maker expects second quarter sales to be 30% higher than a year ago. Inspire sees full-year revenue higher by 26% to 28% from 2023. Inspire Medical Systems (INSP ...
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.